Buerger病下肢动脉腔内治疗的近期与远期结局
该回顾性研究纳入2006至2016年44例Buerger病患者的50条患肢,评估下肢动脉腔内治疗的可行性与结局。技术成功率为80%,3年免于主要不良肢体事件生存率83.3%,免于再干预与截肢生存率67.9%。既往腔内治疗和截肢是再干预与截肢的独立危险因素。
要点
- 腔内治疗对Buerger病下肢动脉病变技术成功率达80%。
- 3年免于再干预与截肢生存率为67.9%。
- 既往腔内治疗和截肢与更差的无再干预截肢生存相关。
核心结论
- 腔内治疗在多数Buerger病病例中实现技术成功,并伴有良好的近期和远期临床结局,可考虑作为严重症状患者的一线治疗选择。
研究设计与样本
- 回顾性分析2006年1月至2016年5月在Severance心血管医院接受腔内治疗的44例Buerger病患者(43例男性,平均年龄40.4±9.6岁)的50条靶肢体。
主要发现
- 86.4%的患者表现为严重肢体缺血,所有肢体均有膝下动脉闭塞,31例(62%)存在髂或股腘动脉的多节段病变。
- 技术成功率为80%,中位随访29个月,3年免于主要不良肢体事件生存率为83.3%,免于再干预与截肢生存率为67.9%。
临床怎么用
- 对于有严重症状的Buerger病患者,腔内治疗可作为一线治疗选择,但需注意既往腔内治疗和截肢史提示再干预与截肢风险较高。
局限性
- 本研究为单中心回顾性分析,样本量较小(44例患者、50条肢体),随访时间中位29个月,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Buerger disease is a rare inflammatory vasculopathy presenting with severe claudication or critical limb ischemia. In this study, we sought to evaluate the feasibility and clinical outcomes of endovascular therapy for Buerger disease involving arteries in the lower extremities. METHODS: Between January 2006 and May 2016, there were 44 Buerger disease patients (43 men; mean age, 40.4 ± 9.6 years) with 50 target limbs treated by endovascular therapy at the Severance Cardiovascular Hospital. Baseline characteristics as well as both immediate and late clinical outcomes were retrospectively analyzed. RESULTS: The majority (86.4%) of patients presented with critical limb ischemia. A total of 88 target lesions in 50 limbs were treated with endovascular procedures. All limbs showed infrapopliteal artery occlusions, and multilevel diseases involving the iliac or femoropopliteal artery were found in 31 patients (62%). Technical success was achieved in 80% of subjects. We found that a lower serum level of C-reactive protein, specifically the log C-reactive protein value (odds ratio, 0.03; 95% confidence interval [CI], 0.00-0.71; P = .030), was an independent predictor of technical failure. The median follow-up duration was 29 months. Major adverse limb event-free survival and reintervention- and amputation-free survival were 83.3% and 67.9% at 3 years, respectively. In a multivariate Cox proportional hazards analysis, previous endovascular treatment (hazard ratio, 3.70; 95% CI, 1.20-11.31; P = .022) and previous amputation (hazard ratio, 4.68; 95% CI, 1.37-15.96; P = .014) were identified as independent risk factors for reintervention- and amputation-free survival. CONCLUSIONS: In patients with Buerger disease, endovascular treatment achieved technical success in the majority of the cases and was associated with favorable immediate and late clinical outcomes. These findings indicate that endovascular therapy may be considered a first-line treatment option for severe symptomatic patients with Buerger disease.
引用
- Kim DH, Ko YG, Ahn CM, et al. Immediate and late outcomes of endovascular therapy for lower extremity arteries in Buerger disease. J Vasc Surg. 2017. PMID: 29157680. doi:10.1016/j.jvs.2017.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。